S.G.Biopharm Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 18.95 Cr
as on 17-11-2024
- Satisfied Charges ₹ 6.41 Cr
as on 17-11-2024
- Revenue 35.04%
(FY 2023)
- Profit -34.52%
(FY 2023)
- Ebitda 223.97%
(FY 2023)
- Net Worth 21.21%
(FY 2023)
- Total Assets 16.52%
(FY 2023)
About S.G.Biopharm
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹18.95 Cr. The company has closed loans amounting to ₹6.41 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anand Trivedi, Amitkumar Trivedi, and Niraj Dholakiya serve as directors at the Company.
- CIN/LLPIN
U24299MH2018PTC312547
- Company No.
312547
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Aug 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at S.G.Biopharm?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niraj Dholakiya  | Director | 19-Jul-2019 | Current |
| Anand Trivedi | Director | 07-Aug-2018 | Current |
| Amitkumar Trivedi | Director | 07-Aug-2018 | Current |
Financial Performance of S.G.Biopharm.
S.G.Biopharm Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.04% increase. The company also saw a substantial fall in profitability, with a 34.52% decrease in profit. The company's net worth Soared by an impressive increase of 21.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S.G.Biopharm?
In 2023, S.G.Biopharm had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmachem Biotech (I) Private LimitedActive 7 years 2 monthsAnand Trivedi and Amitkumar Trivedi are mutual person
- Vetenza Animal Healthcare Private LimitedActive 4 years 10 months
Amitkumar Trivedi is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Apr 2024 | ₹5.40 Cr | Open |
Sidbi Creation Date: 04 Sep 2023 | ₹6.95 M | Open |
Others Creation Date: 06 Jun 2023 | ₹9.71 Cr | Open |
How Many Employees Work at S.G.Biopharm?
Unlock and access historical data on people associated with S.G.Biopharm, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S.G.Biopharm, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S.G.Biopharm's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
